|
|
Article: NeoPharm Announces New Data On Novel Tumor-Targeting Agent in Terminal Brain Cancer.
- Article from:
- Business Wire
- Article date:
- November 19, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors
LAKE FOREST, Ill.--(BUSINESS WIRE)--Nov. 19, 2001
First Clinical Studies in IL13-PE38 for Malignant Glioma
Show Early Potential for Serving Unmet Medical Need
NeoPharm, Inc. (Nasdaq National Market: NEOL) announced preliminary Phase I/II safety and efficacy results for its novel tumor-targeting agent, IL13-PE38, in the treatment of malignant glioma, a fatal form of brain cancer for which there is no known cure. IL13-PE38 was recently granted orphan drug designation from the U.S. Food and Drug Administration (FDA). Three abstracts were presented at the Sixth Annual Meeting of the World Federation of Neuro-Oncology/ ...